1. Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors 
Mitchell S. Cairo, Vanderson Rocha, Eliane Gluckman, Gregory Hale, John Wagner 
Biology of Blood and Marrow Transplantation 
Volume 14, Issue 1, Pages (January 2008)
DOI: /j.bbmt
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
(A) Kaplan-Meier estimates of the time to myeloid engraftment after placental-blood transplantation, according to the dose of leukocytes transfused. (Reprinted from Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients from placental-blood transplants from unrelated donors. N Engl J Med. 1998;339:1569. Copyright © 1998 Massachusetts Medical Society. All Rights Reserved.) (B) Kaplan-Meier estimates of the time to platelet engraftment after placental-blood transplantation, according to the dose of leukocytes transfused. (Reprinted from Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients from placental-blood transplants from unrelated donors. N Engl J Med. 1998;339:1569. Copyright © 1998 Massachusetts Medical Society. All Rights Reserved.)
Biology of Blood and Marrow Transplantation  , 44-53DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) Cumulative proportion surviving after unrelated donor UCB transplantation (n = 102): effect of CD34 cell dose (×105/kilogram recipient body weight). This research was originally published in Wagner J., Barker J., DeFor T., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100:1616. © the American Society of Hematology. (B) Probability of OS by CD34+ cell dose as determined by Kaplan-Meier and Cox's regression multivariate analysis in patients receiving UCB transplantation. CD34+ at or >2.3 × 105 (-----); CD34+ <2.3 × 105 (____) (P = .010, >2.3 versus <2.3 × 105/kg). This research was originally published in Styczynski J, Cheung YK, Garvin J, et al. Unrelated donor transplants: outcomes of unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplant. 2004;34:
Biology of Blood and Marrow Transplantation  , 44-53DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Probability of leukemia-free survival after bone marrow and cord blood transplantation adjusted for disease status at transplantation. (Reprinted from Eapen M, Rubinstein P, Zhang M, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007;369: , with permission from Elsevier.)
Biology of Blood and Marrow Transplantation  , 44-53DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
OS in 268 patients with nonmalignant disorders according to cell dose infused (×107/kg) and HLA differences.
Biology of Blood and Marrow Transplantation  , 44-53DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions